Cargando…
Development of Peptide Vaccines in Dengue
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040172/ https://www.ncbi.nlm.nih.gov/pubmed/28914200 http://dx.doi.org/10.2174/1381612823666170913163904 |
_version_ | 1783338811028144128 |
---|---|
author | Reginald, Kavita Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa |
author_facet | Reginald, Kavita Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa |
author_sort | Reginald, Kavita |
collection | PubMed |
description | Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed. |
format | Online Article Text |
id | pubmed-6040172 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-60401722018-08-01 Development of Peptide Vaccines in Dengue Reginald, Kavita Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa Curr Pharm Des Article Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed. Bentham Science Publishers 2018-03 2018-03 /pmc/articles/PMC6040172/ /pubmed/28914200 http://dx.doi.org/10.2174/1381612823666170913163904 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Reginald, Kavita Chan, Yanqi Plebanski, Magdalena Poh, Chit Laa Development of Peptide Vaccines in Dengue |
title | Development of Peptide Vaccines in Dengue |
title_full | Development of Peptide Vaccines in Dengue |
title_fullStr | Development of Peptide Vaccines in Dengue |
title_full_unstemmed | Development of Peptide Vaccines in Dengue |
title_short | Development of Peptide Vaccines in Dengue |
title_sort | development of peptide vaccines in dengue |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040172/ https://www.ncbi.nlm.nih.gov/pubmed/28914200 http://dx.doi.org/10.2174/1381612823666170913163904 |
work_keys_str_mv | AT reginaldkavita developmentofpeptidevaccinesindengue AT chanyanqi developmentofpeptidevaccinesindengue AT plebanskimagdalena developmentofpeptidevaccinesindengue AT pohchitlaa developmentofpeptidevaccinesindengue |